Nowadays, biological agents such as anti-tumor necrosis factor alpha (anti-TNFα) drugs are used in the treatment of many chronic inflammatory diseases, particularly in those cases that do not respond to conventional treatments. However, infrequently, opportunistic infections such as bacterial, viral, fungal and parasitic infections may develop in patients treated with anti-TNF therapy, and physicians should be cautious in terms of increased risk of infection when using these agents. In this case report, we present a case of bilateral Cytomegalovirus (CMV) pneumonia in an adalimumab treated patient due to ankylosing spondylitis.
Birincil Dil | İngilizce |
---|---|
Konular | Klinik Tıp Bilimleri |
Bölüm | Olgu Sunumu |
Yazarlar | |
Yayımlanma Tarihi | 1 Ocak 2019 |
Gönderilme Tarihi | 4 Eylül 2018 |
Kabul Tarihi | 4 Aralık 2018 |
Yayımlandığı Sayı | Yıl 2019 Cilt: 2 Sayı: 1 |